2Paul C, Wolkenstein P, Adle H, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol,1996, 134(4) :710 -714.
3Friedmann PS, Stricldand I, Pirmohamed M, et al. Investigation of mechanisms in toxic epidermal neerolysis induced by carbamazepine.Arch Dermatol, 1994, 130(5) :598 -604.
4Stone N, Sheerin S, Burge S. Toxic epidermal necrolysis and graft vs.host disease: a clinical spectrum but a diagnostic dilemma. Clin Exp Dermatol, 1999, 24(4) :260 -262.
5Magina S, Lisboa C, Goncalves E, et al. A case of toxic epidermal necrolysis treated with intravenous immunoglobin. Br J Dermatol,2000, 142( 1 ) :191 - 192.
6Paquet P, Jacob E, Damas P, et al. Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins. Burns, 2001, 27(6) :652 -655.
7Correia O, Delgado L, Roujeau JC, et al. Soluble interhukin 2 receptor and interleukin 1 alpha in toxic epidermal necrolysis: a comparative analyais of serum and blister fluid samples. Arch Dermatol,2002, 138(1) :29 -32.
8Correia O, De.lgado L, Barbosa IL, et al. CD8 + lymphocytes in the blister fluid of severe acute cutaneous graft-versus-host disease: further similarities with toxic epidermal necrolysis. Dermatology, 2001,203(3) :212 -216.
9Krammer PH. CD95's deadly mission in the immune system. Nature,2000, 407(6805) :789 -795.
10Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet,1998, 352 (9140) :1586 - 1589.
